Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

Cancer Cell

Volumn 17, Issue 5, 2010, Pages 427-442

  Zhang, Bin ^a   Strauss, Adam C ^a   Chu, Su ^a   Li, Min ^a   Ho, Yinwei ^a   Shiang, Keh Dong ^a   Snyder, David S ^a   Huettner, Claudia S ^b   Shultz, Leonard ^c   Holyoake, Tessa ^d   Bhatia, Ravi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c JACKSON LABORATORY   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CELLCYCLE; DNA; STEMCELL

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; BCR ABL PROTEIN; IMATINIB; PANOBINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENGRAFTMENT; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

EID: 77952105211     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.03.011     Document Type: Article

References (44)

1. Bhatia R., Holtz M., Niu N., Gray R., Snyder D.S., Sawyers C.L., Arber D.A., Slovak M.L., and Forman S.J. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101 (2003) 4701-4707
2. Bhatia R., McGlave P.B., Dewald G.W., Blazar B.R., and Verfaillie C.M. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophages. Blood 85 (1995) 3636-3645
3. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
4. Branford S., Hughes T.P., and Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br. J. Haematol. 107 (1999) 587-599
5. Bruserud O., Stapnes C., Ersvaer E., Gjertsen B.T., and Ryningen A. Histone deacetylase inhibitors in cancer treatment: A review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 8 (2007) 388-400
6. Burgess A., Ruefli A., Beamish H., Warrener R., Saunders N., Johnstone R., and Gabrielli B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23 (2004) 6693-6701
7. Calabretta B., and Perrotti D. The biology of CML blast crisis. Blood 103 (2004) 4010-4022
8. Chen H.Z., Tsai S.Y., and Leone G. Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat. Rev. Cancer 9 (2009) 785-797
9. Chu S., Holtz M., Gupta M., and Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103 (2004) 3167-3174
10. Chu S., Xu H., Shah N.P., Snyder D.S., Forman S.J., Sawyers C.L., and Bhatia R. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105 (2005) 2093-2098
11. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., and Wahl G.M. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66 (2006) 9339-9344
12. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., Barow M., Mountford J.C., and Holyoake T.L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107 (2006) 4532-4539
13. Copland M., Pellicano F., Richmond L., Allan E.K., Hamilton A., Lee F.Y., Weinmann R., and Holyoake T.L. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111 (2008) 2843-2853
14. Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004) 2204-2205
15. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones H., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
16. Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., Rao R., Rocha K., Herger B., Lee F., et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin. Cancer Res. 12 (2006) 5869-5878
17. Fiskus W., Pranpat M., Bali P., Balasis M., Kumaraswamy S., Boyapalle S., Rocha K., Wu J., Giles F., Manley P.W., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108 (2006) 645-652
18. Glaser K.B. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem. Pharmacol. 74 (2007) 659-671
19. Gordon S., Akopyan G., Garban H., and Bonavida B. Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology. Oncogene 25 (2006) 1125-1142
20. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., and Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
21. Holtz M.S., Forman S.J., and Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 19 (2005) 1034-1041
22. Holtz M.S., Slovak M.L., Zhang F., Sawyers C.L., Forman S.J., and Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99 (2002) 3792-3800
23. Holyoake T., Jiang X., Eaves C., and Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94 (1999) 2056-2064
24. Huettner C.S., Koschmieder S., Iwasaki H., Iwasaki-Arai J., Radomska H.S., Akashi K., and Tenen D.G. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood 102 (2003) 3363-3370
25. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M., and Radich J.P. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349 (2003) 1423-1432
26. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., Gotlib J., Li K., Manz M.G., Keating A., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351 (2004) 657-667
27. Jordanides N.E., Jorgensen H.G., Holyoake T.L., and Mountford J.C. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108 (2006) 1370-1373
28. Jorgensen H.G., Allan E.K., Graham S.M., Godden J.L., Richmond L., Elliott M.A., Mountford J.C., Eaves C.J., and Holyoake T.L. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19 (2005) 1184-1191
29. Jorgensen H.G., Allan E.K., Jordanides N.E., Mountford J.C., and Holyoake T.L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109 (2007) 4016-4019
30. Konig H., Holtz M., Modi H., Manley P., Holyoake T.L., Forman S.J., and Bhatia R. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 22 (2008) 748-755
31. Konig H., Holyoake T.L., and Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111 (2008) 2329-2338
32. Larochelle A., Vormoor J., Hanenberg H., Wang J.C., Bhatia M., Lapidot T., Moritz T., Murdoch B., Xiao X.L., Kato I., et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy. Nat. Med. 2 (1996) 1329-1337
33. Laurenti E., Varnum-Finney B., Wilson A., Ferrero I., Blanco-Bose W.E., Ehninger A., Knoepfler P.S., Cheng P.F., MacDonald H.R., Eisenman R.N., et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 3 (2008) 611-624
34. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv. Cancer Res. 91 (2004) 137-168
35. Mathers J., Fraser J.A., McMahon M., Saunders R.D., Hayes J.D., and McLellan L.I. Antioxidant and cytoprotective responses to redox stress. Biochem. Soc. Symp. 71 (2004) 157-176
36. Moon N.S., Frolov M.V., Kwon E.J., Di Stefano L., Dimova D.K., Morris E.J., Taylor-Harding B., White K., and Dyson N.J. Drosophila E2F1 has context-specific pro- and antiapoptotic properties during development. Dev. Cell 9 (2005) 463-475
37. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63 (2003) 5126-5135
38. Nimmanapalli R., Fuino L., Stobaugh C., Richon V., and Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101 (2003) 3236-3239
39. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348 (2003) 994-1004
40. Rousselot P., Huguet F., Rea D., Legros L., Cayuela J.M., Maarek O., Blanchet O., Marit G., Gluckman E., Reiffers J., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
41. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340 (1999) 1330-1340
42. Shultz L.D., Lyons B.L., Burzenski L.M., Gott B., Chen X., Chaleff S., Kotb M., Gillies S.D., King M., Mangada J., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174 (2005) 6477-6489
43. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., and Mesirov J.P. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005) 15545-15550
44. Wang J.C., Lapidot T., Cashman J.D., Doedens M., Addy L., Sutherland D.R., Nayar R., Laraya P., Minden M., Keating A., et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 91 (1998) 2406-2414